Kailera Therapeutics
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Kailera Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Kailera Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Kailera Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2025 |
|---|---|
| 0 | |
| – | |
| -158 | |
| -158 | |
| -149 | |
| -1.26 | |
| – | |
| – | |
| – |
Balance sheet
| In millions of USD | 2025 |
|---|---|
| Total assets | 692 |
| Cash | 160 |
| Total debt | 11 |
| Total liabilities | 1,049 |
| -356 | |
| 118 | |
| – | |
| 41.8% |
Cash flow
| In millions of USD | 2025 |
|---|---|
| -120 | |
| 2 | |
| -122 | |
| Dividends paid | – |
| – | |
| 11 |
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
Not enough data
Questions about Kailera Therapeutics
Is Kailera Therapeutics a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Kailera Therapeutics AI analysis
What does Kailera Therapeutics do?
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. It is in Biotechnology, based in Waltham, MA, United States, with 145 employees.
Does Kailera Therapeutics pay a dividend?
No. Kailera Therapeutics does not pay a dividend at the moment.
Is Kailera Therapeutics stock halal?
Questionable. Kailera Therapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
Who are Kailera Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Kailera Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.